RANITAB

This brand name is authorized in Nigeria. It is also authorized in Turkey.

Active ingredients

The drug RANITAB contains one active pharmaceutical ingredient (API):

1	Ranitidine UNII BK76465IHM - RANITIDINE HYDROCHLORIDE
	Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours.
	Read more about Ranitidine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-8570	Tablet	Ranitab-150 Tablets TAB 150 mg	Each tablet contains: Ranitidine Hydrochloride BP equiv. to Ranitidine 150 mg	02/12/2021
04-8644	Tablet	Ranitab-300 Tablets TAB 300 mg	Each tablet contains: Ranitidine Hydrochloride BP equiv. to Ranitidine 300 mg	02/12/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A02BA02	Ranitidine	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BA H2-receptor antagonists
Discover more medicines within A02BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-8570, 04-8644
TR	İlaç ve Tıbbi Cihaz Kurumu	8699525091147, 8699525091154, 8699525099563, 8699525750143, 8699525753984